NTRA — Natera Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Price data
- Price
- $391.03
- YTD price return
- +70.69%
- YTD total return
- +70.69%
- Next earnings
- Nov 5, 2026 · After close
- Market cap
- 56.4B
- Enterprise value
- 55.5B
- Shares outstanding
- 144.1M
- 52W low
- $181.00
- 52W high
- $437.41
- From 52W high
- -10.60%
- From 52W low
- +116.04%
- 52W range
- 82%$181–$437
- Beta
- 1.50
Volume
- Rel volume
- 1.54×
- 30D volume
- 1.8M
- 30D $ vol
- 724.9M
Insider trading
- Insider net 1W
- −$4.7M
- Insider net 1M
- −$33.7M
- Insider net 3M
- −$110.9M
- Insider net 1Y
- −$324.5M
Form 4 transactions by trade date, as filed; latest on file 2026-11-03.
Fundamentals
- Sales (ttm)
- 2.7B
- Sales/share
- $18.78
- EPS (ttm)
- -$1.37
- FCF (ttm)
- 84.2M
- FCF/share
- $0.58
- Book value/share
- $12.64
- Net margin
- -7.11%
- ROE
- -10.56%
- ROA
- -7.24%
- Current ratio
- 3.00
Growth (CAGR, ttm) · 10Y
- Sales
- +37.85%+42.72%+39.92%+29.03%
- FCF
- -19.48%n/an/an/a
- Shares
- +5.03%+7.94%+8.98%+10.78%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +31.25%+32.21%+28.39%+16.47%
- FCF/share
- -23.34%n/an/an/a
- Book value/share
- +39.21%+34.42%+31.70%+14.86%
- Price
- +99.14%+108.97%+28.72%+47.30%
- Total return
- +99.14%+108.97%+28.72%+47.30%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -284.8×
- Fwd P/E
- -2130.7×
- P/S (ttm)
- 20.8×
- P/B (mrq)
- 30.9×
- P/FCF (ttm)
- 669.4×
- EV/Sales (ttm)
- 20.5×
- FCF yield (ttm)
- 0.15%
- Buyback yield (realized, 1y)
- -5.03%
- Shareholder yield (realized, 1y)
- -5.03%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/S
- 93rd
- P/B
- 90th
Bar = where today’s multiple sits in NTRA’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-04#
Fundamentals#
Operating income
5Y n/m10Y n/mYoY n/mEPS (diluted)
5Y n/m10Y n/mYoY n/mFree cash flow
5Y n/m10Y n/mYoY n/mTTM: operating cash flow $228.2M, capex −$144M
Q2 2026: operating cash flow $54.8M, capex −$63.4M
Shares (diluted)
5Y +68.8%10Y +421.8%YoY +5.1%Net income
5Y n/m10Y n/mYoY n/mAbout Natera#
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners. Natera’s tests are used to support areas such as reproductive health, cancer residual disease monitoring, recurrence surveillance, and organ transplant management. Headquartered in Austin, Texas, Natera plays an important role in the growing precision medicine market by providing non-invasive diagnostic tools that help inform clinical decision-making across multiple medical specialties.
Austin, TX·4,424 employees·Diagnostics & Research·natera.com·As of Oct 28, 2026
Recent filings#
- Aug 6Earnings · Earnings release — EPS −$0.47 vs −$0.47 est. (+0.0%); revenue $752.8M (+38% y/y) 21.4%
ETFs holding NTRA#
24 of the 193 ETFs ChartRow carries live hold NTRA. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 2.9% |
| ARKK | ARK Innovation ETF | 1.2% |
| XBI | SPDR S&P Biotech ETF | 1.2% |
| VBK | Vanguard Small-Cap Growth ETF | 1.0% |
| IWP | iShares Russell Mid-Cap Growth ETF | 1.0% |
| VHT | Vanguard Health Care ETF | 0.6% |
| VXF | Vanguard Extended Market ETF | 0.5% |
| VB | Vanguard Small-Cap ETF | 0.4% |
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +24.07% | +0.61% |
| JNJ | Johnson & Johnson | +7.92% | +3.81% |
| ABBV | AbbVie Inc. | +12.18% | +3.09% |
| MRK | Merck & Co. Inc. | +4.20% | +3.93% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +10.08% | +1.22% |
| NVS | Novartis AG | +17.01% | +3.59% |
| TMO | Thermo Fisher Scientific Inc. | +7.84% | +1.12% |
| AMGN | Amgen Inc. | +18.69% | +3.71% |
